Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated July 31, 2025, titled "Press Release and presentation on the financials and operational performance ofthe Company for the first quarter ended June 30, 2025".
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Ingrevia posted Q1FY26 revenue of Rs 1,038 Cr, up 1% YoY but down 1% QoQ. EBITDA rose 29% YoY to Rs 153 Cr with margin expanding to 15% (from 12%), driven by cost optimization and better mix. Net profit jumped 54% YoY to Rs 75 Cr, with EPS at Rs 4.7. The Specialty Chemicals segment was the standout, growing revenue 11% YoY and EBITDA 52% YoY, now contributing 90% of total EBITDA. Chemical Intermediates remained weak with EBITDA falling 53% YoY due to pricing pressure. Management confirmed the $300M Agro CDMO order is on track for early 2026, with the pharma CDMO funnel doubling in size and 12+ opportunities in the semiconductor pipeline.
Strong YoY earnings growth and margin expansion in the high-value Specialty Chemicals business are positives for shareholders, supporting growth narrative. However, sequential softness, weakness in Chemical Intermediates, and rising net debt (Rs 700 Cr from Rs 658 Cr) along with heavy capex commitments may limit near-term upside. Watch for execution of the big CDMO order and cost savings from the Lean 2.0 program.